A perfect example in this regard is the fact that ADAM17 inhibitors are often cited as a potential stroke therapeutic under the premise that they could ultimately limit excessive innate-driven inflammation and its associated complications via a reduction in TNFα production62–65. This evidence concerns the gene ADAM17 and stroke disorder.